A protein deficiency that should weaken cancer cells actually makes them grow faster
When a key energy-producing protein is reduced in cancer cells, the tumors don’t slow down — they accelerate. New research reveals a metabolic paradox at the heart of cancer biology.
Inside every cell, mitochondria convert nutrients into usable energy through a chain of molecular reactions. One critical component of that chain is the electron transfer flavoprotein, or ETF — a protein complex that shuttles electrons between metabolic pathways. In healthy people, a severe deficiency in ETF causes a rare inherited disease called multiple acyl-CoA dehydrogenase deficiency, which can be life-threatening. But a new study published in eLife reveals something unexpected: a milder reduction in ETF activity, in cancer cells, doesn’t hinder tumor growth. It enhances it.
Researchers studied multiple human cancer cell lines and mouse models in which expression of the gene ETFDH — which encodes a key ETF subunit — was reduced. What they found defied simple logic. On one hand, the cancer cells lost metabolic flexibility: they became less capable of switching between different fuel sources, such as fatty acids and amino acids. On the other hand, their overall energy output paradoxically increased. The cells effectively specialised — trading versatility for raw bioenergetic output, and in doing so, accelerating their own growth.
How cancer hijacks a metabolic weakness
This finding fits into a broader understanding of how cancer cells rewire their metabolism to thrive in hostile conditions — low oxygen, nutrient scarcity, immune attack. The classic observation is the Warburg effect: cancer cells preferentially use a less efficient form of energy production even when oxygen is available. The new data adds nuance to this picture. Within mitochondrial energy metabolism itself, cancer cells can adopt a specific configuration that promotes growth — even when that configuration would be considered a deficiency in normal tissue.
The tissue-specific contrast is telling. In muscle cells, the ETF gene is essential — its loss causes direct harm. In acute lymphoblastic leukemia cells (the NALM6 line at the centre of this study), it is not. This difference suggests that cancer cells have effectively co-opted a metabolic liability, turning what would be a disease-causing defect in healthy tissue into a growth advantage.
The therapeutic implications cut both ways
For cancer treatment, the findings point in two directions at once. The reduced metabolic flexibility of ETF-deficient cancer cells may represent a vulnerability: if these tumors are dependent on a narrow set of fuel sources, blocking those sources could be disproportionately effective. That’s a potential therapeutic angle worth exploring.
But the study also raises a warning. Therapies designed to restore ETF function — on the assumption that more is better — could backfire. If restoring ETF activity grants cancer cells greater metabolic flexibility, it might inadvertently help them survive and adapt to treatment rather than succumb to it.
The research is still preclinical, conducted in cell cultures and mouse models. The path to human therapies is long. But it adds to a mounting body of evidence that cancer metabolism rarely behaves intuitively — and that interventions designed around healthy-cell biology can produce the opposite of the intended effect when applied to a tumor.